Anidulafungin
| Evidensnivå: L5 | Förutsagda indikationer: 0 st |
Innehållsförteckning
Based on the Evidence Pack, I'll generate the report. Note that this is a data-sparse case: no TxGNN predicted indications, no Taiwan market presence, and several data gaps. I'll leverage my pharmacological knowledge of Anidulafungin to supplement.
Anidulafungin: Antifungal Agent — Drug Repurposing Candidate Assessment
One-Sentence Summary
Anidulafungin is an echinocandin-class antifungal agent primarily used for the treatment of candidemia and invasive candidiasis. The TxGNN model did not generate any predicted new indications for this drug in the current analysis cycle, and no clinical trial or literature evidence has been assembled for a repurposing direction.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Candidemia, invasive candidiasis (esophageal candidiasis) |
| Predicted New Indication | — (No TxGNN prediction available) |
| TxGNN Prediction Score | — |
| Evidence Level | L5 (No prediction or supporting evidence) |
| Taiwan Market Status | ✗ Not marketed (未上市) |
| Number of Authorizations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, the TxGNN model has not generated a repurposing prediction for Anidulafungin. Without a predicted new indication, a mechanistic plausibility analysis cannot be conducted.
For reference, Anidulafungin (brand name: Eraxis) is a semisynthetic echinocandin antifungal that works by inhibiting β-(1,3)-D-glucan synthase, an enzyme essential for fungal cell wall synthesis. This mechanism is highly specific to fungi—β-(1,3)-D-glucan is not present in mammalian cells—which gives echinocandins a favorable safety profile but also limits the obvious mechanistic bridges to non-fungal disease areas.
The Evidence Pack notes that detailed mechanism of action data was flagged as a data gap (DG002, severity: High). While the MOA is well-characterized in pharmacological literature as described above, this gap in the structured dataset may have contributed to the absence of a TxGNN prediction. Resolving this data gap and re-running the prediction model is recommended before concluding that no repurposing opportunities exist.
Clinical Trial Evidence
Currently no related clinical trials registered for a repurposing indication.
No predicted indication was generated by TxGNN; therefore, no targeted clinical trial search was performed.
Literature Evidence
Currently no related literature available for a repurposing indication.
No predicted indication was generated by TxGNN; therefore, no targeted literature search was performed.
Taiwan Market Information
Anidulafungin currently holds no marketing authorizations in Taiwan (TFDA). The drug is not marketed domestically.
| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| — | — | — | No Taiwan licenses found |
Note: Anidulafungin is marketed internationally under the brand name Eraxis (Pfizer) and is approved by the US FDA and EMA for candidemia and invasive candidiasis. Its absence from the Taiwan market represents an additional barrier to any domestic repurposing initiative.
Safety Considerations
Please refer to the package insert for safety information.
The Evidence Pack contains the following unresolved data gaps that affect safety assessment:
- Key Warnings: Not available — TFDA package insert data not yet retrieved (Data Gap DG001, severity: Blocking)
- Contraindications: Not available — pending package insert parsing
- Drug Interactions: Query returned no results (DDI database search: not found)
Known safety profile from international references (for context):
- Anidulafungin is generally well-tolerated; common adverse effects include diarrhea, nausea, hypokalemia, and elevated hepatic enzymes
- Histamine-mediated infusion-related reactions (flushing, rash, hypotension) can occur if infusion rate is too rapid
- Hepatotoxicity (including hepatic failure) has been reported rarely
- No significant cytochrome P450-mediated drug interactions are expected, as anidulafungin undergoes slow chemical degradation rather than hepatic metabolism
Conclusion and Next Steps
Decision: Hold
Rationale: TxGNN did not produce any predicted new indication for Anidulafungin. Combined with the absence of Taiwan market authorization and multiple blocking-level data gaps, there is currently insufficient basis to advance this candidate through the repurposing pipeline.
To proceed, the following is needed:
- Resolve MOA data gap (DG002) — Populate the structured MOA field from DrugBank and re-run TxGNN prediction to determine whether a valid repurposing signal emerges
- Resolve TFDA package insert data gap (DG001) — Download and parse the international package insert (or Eraxis US PI) to populate safety warnings and contraindications, enabling S1 safety screening
- Assess Taiwan market pathway — Since Anidulafungin has zero Taiwan licenses, any repurposing initiative would require either import via special approval channels or a new drug application, adding significant regulatory complexity
- Re-evaluate after data gaps resolved — Once MOA and safety data are integrated, re-run the full evidence pipeline (TxGNN prediction → clinical trial search → literature search) before making a Go/No-Go decision
Ansvarsfriskrivning
Detta innehåll är endast avsett för forskningsändamål och utgör inte medicinsk rådgivning. Klinisk validering krävs före klinisk tillämpning.